Skip to main content
Erschienen in: Current Atherosclerosis Reports 4/2015

01.04.2015 | Women and Ischemic Heart Disease (M Gulati, Section Editor)

Atherosclerotic Vascular Disease in the Autoimmune Rheumatologic Patient

verfasst von: Rekha Mankad

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have a strong association with an increased risk of atherosclerotic cardiovascular diseases (ASCVD), particularly ischemic heart disease (IHD). A majority of the autoimmune conditions occur predominantly in women, and as women continue to experience a higher cardiovascular mortality compared to men, this potential added risk factor must be recognized. Inflammation and immune mechanisms have been shown to be an underlying mechanism for the development of atherosclerosis, thus sharing a common mechanism with rheumatologic conditions. There is an under recognition, in both patient and physician, of the increased cardiovascular (CV) risk within the autoimmune population, with present CV risk profile algorithms performing poorly in these patients. Traditional risk factors play a role in the development of IHD in the autoimmune patient, but their overall significance is unclear and does not fully explain the elevated CV risk. The role of inflammation and risk factors in autoimmune conditions, and their link to the elevated CV risk will be explored within this article.
Literatur
1.
Zurück zum Zitat Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–62.PubMedCentralPubMed Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–62.PubMedCentralPubMed
2.
Zurück zum Zitat Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953;249:553–6.PubMed Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953;249:553–6.PubMed
3.
Zurück zum Zitat Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221–5.PubMed Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221–5.PubMed
4.
Zurück zum Zitat Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337–47.PubMed Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337–47.PubMed
5.
Zurück zum Zitat Chu S-Y, Chen Y-J, Liu C-J, Tseng W-C, Lin M-W, Hwang C-Y, et al. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med. 2013;126:982–8.PubMed Chu S-Y, Chen Y-J, Liu C-J, Tseng W-C, Lin M-W, Hwang C-Y, et al. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med. 2013;126:982–8.PubMed
6.
Zurück zum Zitat Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27:174–82.PubMed Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27:174–82.PubMed
7.
Zurück zum Zitat Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.PubMed Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.PubMed
8.
Zurück zum Zitat Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMed Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMed
9.
Zurück zum Zitat Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol. 1980;100:57–80.PubMedCentralPubMed Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol. 1980;100:57–80.PubMedCentralPubMed
10.
Zurück zum Zitat Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169–75.PubMedCentralPubMed Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169–75.PubMedCentralPubMed
11.
Zurück zum Zitat Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2009;29:1714–7.PubMed Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2009;29:1714–7.PubMed
12.
Zurück zum Zitat Aubry M-C, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937–42.PubMed Aubry M-C, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937–42.PubMed
13.
Zurück zum Zitat Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81.PubMed Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81.PubMed
14.
Zurück zum Zitat Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–91.PubMed Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–91.PubMed
15.
Zurück zum Zitat Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–26.PubMed Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–26.PubMed
16.
Zurück zum Zitat Jara LJ, Medina G, Vera-Lastra O, Amigo M-C. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev. 2006;5:195–201.PubMed Jara LJ, Medina G, Vera-Lastra O, Amigo M-C. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev. 2006;5:195–201.PubMed
17.
Zurück zum Zitat Bartoloni E, Alunno A, Bistoni O, Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev. 2010;9:701–7.PubMed Bartoloni E, Alunno A, Bistoni O, Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev. 2010;9:701–7.PubMed
18.
Zurück zum Zitat Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DPM. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010–9.PubMed Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DPM. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010–9.PubMed
19.
Zurück zum Zitat Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009;11:217.PubMedCentralPubMed Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009;11:217.PubMedCentralPubMed
20.
Zurück zum Zitat Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMed Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMed
21.
Zurück zum Zitat Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. Cd4+Cd28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109:2744–8.PubMed Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. Cd4+Cd28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109:2744–8.PubMed
22.
Zurück zum Zitat Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011;63:178–83. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011;63:178–83.
23.
Zurück zum Zitat Bruce IN. Atherogenesis and autoimmune disease: the model of lupus. Lupus. 2005;14:687–90.PubMed Bruce IN. Atherogenesis and autoimmune disease: the model of lupus. Lupus. 2005;14:687–90.PubMed
24.
Zurück zum Zitat Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus. 2008;17:878–87.PubMed Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus. 2008;17:878–87.PubMed
25.
Zurück zum Zitat Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases—mechanisms and clinical findings. Clin Rev Allergy Immunol. 2009;37:20–8.PubMed Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases—mechanisms and clinical findings. Clin Rev Allergy Immunol. 2009;37:20–8.PubMed
26.
Zurück zum Zitat Shoenfeld Y, Harats D, George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled? Lupus. 1998;7 Suppl 2:S140–3.PubMed Shoenfeld Y, Harats D, George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled? Lupus. 1998;7 Suppl 2:S140–3.PubMed
27.
Zurück zum Zitat Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923–5.PubMed Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923–5.PubMed
28.
Zurück zum Zitat Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:338–46.PubMed Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:338–46.PubMed
29.
Zurück zum Zitat Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408–15.PubMed Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408–15.PubMed
30.
Zurück zum Zitat Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–15.PubMed Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–15.PubMed
31.
Zurück zum Zitat Maksimowicz-McKinnon K, Selzer F, Manzi S, Kip KE, Mulukutla SR, Marroquin OC, et al. Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute dynamic registry. Circ Cardiovasc Interv. 2008;1:201–8.PubMedCentralPubMed Maksimowicz-McKinnon K, Selzer F, Manzi S, Kip KE, Mulukutla SR, Marroquin OC, et al. Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute dynamic registry. Circ Cardiovasc Interv. 2008;1:201–8.PubMedCentralPubMed
32.
Zurück zum Zitat SHAH MA, SHAH AM, KRISHNAN E. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol. 2009;36:570–5.PubMed SHAH MA, SHAH AM, KRISHNAN E. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol. 2009;36:570–5.PubMed
33.
Zurück zum Zitat Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum. 2004;50:3170–6.PubMed Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum. 2004;50:3170–6.PubMed
34.
Zurück zum Zitat Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol. 2003;25:79–88.PubMed Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol. 2003;25:79–88.PubMed
35.
Zurück zum Zitat Jara LJ, Medina G, Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allergy Immunol. 2007;32:172–7.PubMed Jara LJ, Medina G, Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allergy Immunol. 2007;32:172–7.PubMed
36.
Zurück zum Zitat Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23–7.PubMed Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23–7.PubMed
37.
Zurück zum Zitat Artenjak A, Lakota K, Frank M, Cucnik S, Rozman B, Bozic B, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev. 2012;11:873–82.PubMed Artenjak A, Lakota K, Frank M, Cucnik S, Rozman B, Bozic B, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev. 2012;11:873–82.PubMed
38.
Zurück zum Zitat Gualtierotti R, Biggioggero M, Meroni P. Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol. 2013;44:51–6.PubMed Gualtierotti R, Biggioggero M, Meroni P. Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol. 2013;44:51–6.PubMed
39.
Zurück zum Zitat Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72:1188–93.PubMed Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72:1188–93.PubMed
40.
Zurück zum Zitat Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54–8.PubMed Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54–8.PubMed
41.
Zurück zum Zitat Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198–200.PubMed Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198–200.PubMed
42.
Zurück zum Zitat Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–7.PubMed Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–7.PubMed
43.
Zurück zum Zitat Van Doornum S, Brand C, King B, Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2061–8.PubMed Van Doornum S, Brand C, King B, Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2061–8.PubMed
44.
Zurück zum Zitat Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402–11.PubMed Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402–11.PubMed
45.
Zurück zum Zitat Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum. 2009;60:2861–9.PubMed Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum. 2009;60:2861–9.PubMed
46.
Zurück zum Zitat Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004;110:1774–9.PubMed Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004;110:1774–9.PubMed
47.
Zurück zum Zitat Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583–7.PubMed Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583–7.PubMed
48.
Zurück zum Zitat Van Doornum S, Brand C, Sundararajan V, Ajani AE, Wicks IP. Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population. Arthritis Res Ther. 2010;12:R183.PubMedCentralPubMed Van Doornum S, Brand C, Sundararajan V, Ajani AE, Wicks IP. Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population. Arthritis Res Ther. 2010;12:R183.PubMedCentralPubMed
49.
Zurück zum Zitat Francis ML, Varghese JJ, Mathew JM, Koneru S, Scaife SL, Zahnd WE. Outcomes in patients with rheumatoid arthritis and myocardial infarction. Am J Med. 2010;123:922–8.PubMed Francis ML, Varghese JJ, Mathew JM, Koneru S, Scaife SL, Zahnd WE. Outcomes in patients with rheumatoid arthritis and myocardial infarction. Am J Med. 2010;123:922–8.PubMed
50.
Zurück zum Zitat Varghese JJ, Koneru S, Scaife SL, Zahnd WE, Francis ML. Mortality after coronary artery revascularization of patients with rheumatoid arthritis. J Thorac Cardiovasc Surg. 2010;140:91–6.PubMed Varghese JJ, Koneru S, Scaife SL, Zahnd WE, Francis ML. Mortality after coronary artery revascularization of patients with rheumatoid arthritis. J Thorac Cardiovasc Surg. 2010;140:91–6.PubMed
51.•
Zurück zum Zitat McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, et al. Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. J Rheumatol. 2013;40:605–10. This study specifically identifies that patient with RA have worse outcomes after a myocardial infarction, despite similar treatment approach. RA patients are treated with guideline based therapy for their acute presentation like a non-RA patient, so their increased risk is likely due to their autoimmune disease itself.PubMedCentralPubMed McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, et al. Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. J Rheumatol. 2013;40:605–10. This study specifically identifies that patient with RA have worse outcomes after a myocardial infarction, despite similar treatment approach. RA patients are treated with guideline based therapy for their acute presentation like a non-RA patient, so their increased risk is likely due to their autoimmune disease itself.PubMedCentralPubMed
52.
Zurück zum Zitat Eckel RH, Alberti K, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2010;375:181–183. Eckel RH, Alberti K, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2010;375:181–183.
53.
Zurück zum Zitat Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993;20:1830–5.PubMed Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993;20:1830–5.PubMed
54.
Zurück zum Zitat Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21:279–83.PubMedCentralPubMed Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21:279–83.PubMedCentralPubMed
55.
Zurück zum Zitat Boyer J-F, Gourraud P-A, Cantagrel A, Davignon J-L, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78:179–83.PubMed Boyer J-F, Gourraud P-A, Cantagrel A, Davignon J-L, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78:179–83.PubMed
56.
Zurück zum Zitat Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci. 2005;1051:281–90.PubMed Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci. 2005;1051:281–90.PubMed
57.
Zurück zum Zitat Gonzalez A, Kremers HM, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64–9.PubMed Gonzalez A, Kremers HM, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64–9.PubMed
58.
Zurück zum Zitat Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003;48:3159–67.PubMed Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003;48:3159–67.PubMed
59.
Zurück zum Zitat Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Care Res. 2008;59:176–80. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Care Res. 2008;59:176–80.
60.
Zurück zum Zitat Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34:70–5.PubMed Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34:70–5.PubMed
61.
Zurück zum Zitat Urowitz MB, Gladman D, Ibañez D, Bae SC, Sanchez-Guerrero J, Gordon C, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res. 2010;62:881–7. Urowitz MB, Gladman D, Ibañez D, Bae SC, Sanchez-Guerrero J, Gordon C, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res. 2010;62:881–7.
62.
Zurück zum Zitat Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–9.PubMed Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–9.PubMed
63.
Zurück zum Zitat Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51–60.PubMed Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51–60.PubMed
64.
Zurück zum Zitat Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Rheumatology. 2011;50:324–9.PubMed Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Rheumatology. 2011;50:324–9.PubMed
65.•
Zurück zum Zitat Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res. 2013;65:2046–50. Review of the role lipid abnormalities have in the RA patient in regards to prevalence and overall impact in CV events. Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res. 2013;65:2046–50. Review of the role lipid abnormalities have in the RA patient in regards to prevalence and overall impact in CV events.
66.
Zurück zum Zitat Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-Related Mortality Risk (AMORIS) study. Ann Rheum Dis. 2010;69:1996–2001.PubMed Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-Related Mortality Risk (AMORIS) study. Ann Rheum Dis. 2010;69:1996–2001.PubMed
67.
Zurück zum Zitat Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69:1310–4.PubMedCentralPubMed Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69:1310–4.PubMedCentralPubMed
68.
Zurück zum Zitat Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007;28:69–75.PubMed Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007;28:69–75.PubMed
69.
Zurück zum Zitat Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482–7.PubMedCentralPubMed Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482–7.PubMedCentralPubMed
70.
Zurück zum Zitat Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. The Lancet. 2004;364:937–952. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. The Lancet. 2004;364:937–952.
71.
Zurück zum Zitat Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–72.PubMed Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–72.PubMed
72.
Zurück zum Zitat Panoulas VF, Douglas KMJ, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology. 2007;46:1477–82.PubMed Panoulas VF, Douglas KMJ, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology. 2007;46:1477–82.PubMed
73.
Zurück zum Zitat Rahman P, Aguero S, Gladman D, Hallett D, Urowitz M. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus. 2000;9:672–5.PubMed Rahman P, Aguero S, Gladman D, Hallett D, Urowitz M. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus. 2000;9:672–5.PubMed
74.
Zurück zum Zitat Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54:2765–75.PubMed Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54:2765–75.PubMed
75.
Zurück zum Zitat Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5.PubMedCentralPubMed Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5.PubMedCentralPubMed
76.
Zurück zum Zitat Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58:2105–12.PubMedCentralPubMed Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58:2105–12.PubMedCentralPubMed
77.
Zurück zum Zitat Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196:756–63.PubMed Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196:756–63.PubMed
78.
Zurück zum Zitat Crowson CS, Myasoedova E, Davis 3rd JM, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. Journal Rheumatol. 2011;38:29–35. Crowson CS, Myasoedova E, Davis 3rd JM, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. Journal Rheumatol. 2011;38:29–35.
79.
Zurück zum Zitat Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187–93.PubMed Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187–93.PubMed
80.
Zurück zum Zitat Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case–control study in Norfolk, England. Arthritis Rheum. 1997;40:1955–61.PubMed Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case–control study in Norfolk, England. Arthritis Rheum. 1997;40:1955–61.PubMed
81.
Zurück zum Zitat Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology. 1994;5:525–32.PubMed Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology. 1994;5:525–32.PubMed
82.
Zurück zum Zitat Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Douglas KM, Nevill AM, Jamurtas AZ, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:242–5.PubMed Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Douglas KM, Nevill AM, Jamurtas AZ, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:242–5.PubMed
83.
Zurück zum Zitat Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50:3450–7.PubMed Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50:3450–7.PubMed
84.
Zurück zum Zitat Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165:1624–9.PubMed Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165:1624–9.PubMed
85.••
Zurück zum Zitat Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420–4. Underscores how traditional CV risk scoring tools are not as beneficial in the patient with RA and that we must look beyond those factors to fully understand an RA patient’s overall risk of heart disease.PubMedCentralPubMed Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420–4. Underscores how traditional CV risk scoring tools are not as beneficial in the patient with RA and that we must look beyond those factors to fully understand an RA patient’s overall risk of heart disease.PubMedCentralPubMed
86.
Zurück zum Zitat Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Berger RD, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–7.PubMed Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Berger RD, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–7.PubMed
87.
Zurück zum Zitat Crowson CS, Therneau TM, Davis JM, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum. 2013;65:2562–6.PubMedCentralPubMed Crowson CS, Therneau TM, Davis JM, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum. 2013;65:2562–6.PubMedCentralPubMed
88.
Zurück zum Zitat Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58:2268–74.PubMed Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58:2268–74.PubMed
89.
Zurück zum Zitat Peters MJL, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Care Res. 2009;61:1571–9. Peters MJL, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Care Res. 2009;61:1571–9.
90.
Zurück zum Zitat Bruce IN. ‘Not only…But also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005;44:1492–502.PubMed Bruce IN. ‘Not only…But also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005;44:1492–502.PubMed
91.
Zurück zum Zitat Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50:3444–9.PubMed Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50:3444–9.PubMed
92.
Zurück zum Zitat Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää DS. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91.PubMed Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää DS. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91.PubMed
93.
Zurück zum Zitat Szekanecz Z, Kerekes G, DÉR H, SÁNdor Z, SzabÓ Z, VÉGvÁRi A, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:349–58.PubMed Szekanecz Z, Kerekes G, DÉR H, SÁNdor Z, SzabÓ Z, VÉGvÁRi A, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:349–58.PubMed
94.
Zurück zum Zitat Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52:2293–9.PubMed Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52:2293–9.PubMed
95.
Zurück zum Zitat Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2007;66:486–92.PubMedCentralPubMed Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2007;66:486–92.PubMedCentralPubMed
96.
Zurück zum Zitat Liang KP, Maradit-Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36:2462–9.PubMedCentralPubMed Liang KP, Maradit-Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36:2462–9.PubMedCentralPubMed
97.
Zurück zum Zitat Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.PubMed Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.PubMed
98.
Zurück zum Zitat Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.PubMed Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.PubMed
99.
Zurück zum Zitat Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, BELL A, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the Lupus and Atherosclerosis Evaluation of Risk (LASER) study. J Rheumatol. 2010;37:322–9.PubMed Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, BELL A, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the Lupus and Atherosclerosis Evaluation of Risk (LASER) study. J Rheumatol. 2010;37:322–9.PubMed
100.
Zurück zum Zitat McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541–9.PubMed McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541–9.PubMed
101.
Zurück zum Zitat Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.PubMedCentralPubMed Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.PubMedCentralPubMed
102.
Zurück zum Zitat Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790–8.PubMed Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790–8.PubMed
103.
Zurück zum Zitat Naranjo A, Sokka T, Descalzo M, Calvo-Alen J, Horslev-Petersen K, Luukkainen R, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.PubMedCentralPubMed Naranjo A, Sokka T, Descalzo M, Calvo-Alen J, Horslev-Petersen K, Luukkainen R, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.PubMedCentralPubMed
104.
Zurück zum Zitat Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010;49:295–307.PubMed Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010;49:295–307.PubMed
105.
Zurück zum Zitat van Halm V, Nurmohamed M, Twisk J, Dijkmans B, Voskuyl A. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8:R151.PubMedCentralPubMed van Halm V, Nurmohamed M, Twisk J, Dijkmans B, Voskuyl A. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8:R151.PubMedCentralPubMed
106.
Zurück zum Zitat Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA l). Ann Rheum Dis. 2007;66:1168–72.PubMedCentralPubMed Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA l). Ann Rheum Dis. 2007;66:1168–72.PubMedCentralPubMed
Metadaten
Titel
Atherosclerotic Vascular Disease in the Autoimmune Rheumatologic Patient
verfasst von
Rekha Mankad
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 4/2015
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-015-0497-6

Weitere Artikel der Ausgabe 4/2015

Current Atherosclerosis Reports 4/2015 Zur Ausgabe

Coronary Heart Disease (E Gianos and B Shah, Section Editor)

Treatment of Dyslipidemia in HIV

Genetics (AJ Marian, Section Editor)

Targeting PCSK9 for Therapeutic Gains

New Drugs Approved for Homozygous FH (SS Virani, Section Editor)

Genetics of Familial Hypercholesterolemia

Nonstatin Drugs (EM deGoma, Section Editor)

Red Yeast Rice for the Treatment of Dyslipidemia

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.